Ariad Pharmaceuticals Inc fka ARIA

[Whosetosay]

Sadly, the management does deserve the criticism.

The article today essentially confirms the label for Ponatinib is correct. Any additional future use is 3-5 years away whether as a standalone or incombination therapy (of which there are no significant trials, or maybe 1 or 2.) Pona cannot sustain it's own existence, much less that of Ariad.

That leaves the burden on the shoulders of '113 and mN. That is where Ariad should be focusing all it's attention. '113 could be bic. mN must, absolutely must be a winner. To tout Pona as the key to Ariad's success is mistaken. Pona is the key to its current limp-along morass, and will be for years.